Vilnius-based digital health company Self.co, formerly known as Allergomedica, has secured €2.56 million in combined venture and grant funding to revolutionize how allergies and food intolerances are diagnosed. The round includes €1.2 million in venture investment led by Iron Wolf Capital, alongside Coinvest, NGL Ventures, and several angel investors, complemented by a €1.36 million grant from Innovation Agency Lithuania. This capital will accelerate the company’s European expansion and further development of its molecular testing technology.
Affordable and Precise Diagnostics
Allergies and intolerances affect nearly 40% of the global population, yet conventional testing remains costly and inaccessible, often priced between €200 and €400 with long wait times. Self.co aims to change this by offering affordable molecular-level allergy and intolerance tests priced between €69 and €99, providing fast and reliable results via its digital health platform. The company’s approach combines laboratory precision with AI-driven analysis, giving users personalized insights and actionable treatment plans.
Origins and Innovation
Founded in 2015 by Gintautas Gylys and his son, CEO Tautvydas Gylys, Self.co was built to make allergy diagnostics more accessible and data-driven. The idea emerged from Gintautas’s experience running an allergy clinic, where he noticed existing tests were often inaccurate and prohibitively expensive. Together, the founders developed a proprietary microarray platform capable of identifying more than 300 allergens and food markers from a small blood sample collected at home or through partner clinics.
Technology Behind the Platform
Self.co’s molecular diagnostic system combines advanced bioscience and AI to produce precise, personalized results. Its microarray platform processes each sample with molecular-level accuracy and interprets the data using algorithms trained on medical insights and expert reviews. The output is a comprehensive digital report that includes avoidance strategies and tailored recommendations, empowering users to manage their health independently and effectively.
Market Position and Competitors
The company’s technology offers a disruptive alternative to traditional allergy testing providers like ALK-Abelló and Thermo Fisher Scientific, which rely on slower and more expensive skin prick or ImmunoCAP tests. In the digital testing segment, platforms such as EverlyWell and 23andMe provide limited allergen panels, making Self.co’s offering significantly broader in scope and precision. By controlling every stage of the process—from technology development to lab analysis—Self.co ensures cost efficiency and clinical reliability unmatched by most competitors.
Backing and Strategic Vision
Iron Wolf Capital Managing Partner Kasparas Jurgelionis emphasized the platform’s potential to reshape global allergy care, stating that Self.co is addressing long-standing inefficiencies for patients and clinicians. The venture capital firm, which invests across the Baltics and beyond, sees Self.co as part of a new wave of healthtech companies combining deep science and user-friendly technology. The funding will support the startup’s expansion into Germany, Austria, Ireland, and the UK, while also enhancing its testing systems and integrating long-term digital management tools.
Future Plans
Self.co’s next phase involves transforming its platform into a comprehensive digital health ecosystem for allergy and intolerance management. The company plans to launch a smart questionnaire to help users pinpoint symptom causes and select the right tests. Future developments will include a proprietary dry-blood collection device, broader intolerance panels such as lactose and histamine, and strategic partnerships with insurers to increase accessibility and adoption across Europe.
With its new funding and growing European footprint, Self.co is positioning itself at the forefront of digital diagnostics. By merging molecular science with accessible, data-driven healthcare, the startup aims to empower millions to take control of their allergy and intolerance symptoms. Its ambition to become Europe’s leading digital platform for allergy management by 2030 underscores both its technological edge and its patient-centered mission.